MRK Stock Recent News
MRK LATEST HEADLINES
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Gynecologic Cancers.
In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYNOTE-006 trial, evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced melanoma. Based on 10 years of follow-up, the data showed sustained improved survival outcomes for patients receiving KEYTRUDA as a single agent compared to ipilimumab in patients with advanced melanoma. The.
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA in Combination With TACE Significantly Improved PFS Compared to TACE Alone in Patients With Unresectable, Non-Metastatic HCC.
Its blockbuster Keytruda cancer drug is scheduled to lose patent protection by the end of this decade. The company is betting on an extensive candidate pipeline and new indications to drive long-term growth.
Merck's 15% decline in July is presenting investors with an intermediate to long-term buying opportunity. Long-term trend lines and Bollinger Bands indicate strong support at $110. We expect Merck to return to the July high of $133. Sentiment indicators show "too many" investors expect lower prices for Merck, which is a positive signal for higher prices.